Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Icatibant (Firazyr) vs Ziconotide (Prialt)
An educational, source-based comparison of Icatibant (Firazyr) and Ziconotide (Prialt) — how each peptide works, what it's researched for, and what to know before going deeper.
Bradykinin B2 receptor antagonist for hereditary angioedema attacks.
Synthetic decapeptide that competitively blocks the bradykinin B2 receptor, halting the vascular leak that drives HAE swelling attacks.
- Hereditary angioedema (acute attacks)
- • FDA-approved.
- • Injection-site reactions very common.
Synthetic ω-conopeptide for severe chronic pain via intrathecal infusion.
Synthetic version of ω-conotoxin MVIIA from cone snail Conus magus; selectively blocks N-type voltage-gated calcium channels on primary afferent nerve terminals in the spinal dorsal horn, inhibiting nociceptive neurotransmitter release.
- Severe chronic pain refractory to systemic analgesics, intrathecal morphine
- • FDA-approved.
- • Black-box warning for severe psychiatric and neurologic effects.
- • Contraindicated in history of psychosis.
Icatibant (Firazyr) vs Ziconotide (Prialt) — Key differences
- Class: Icatibant (Firazyr) is classified as Bradykinin Antagonist · Immunology, while Ziconotide (Prialt) is N-type Calcium Channel Blocker · Analgesic.
- Primary research focus: Icatibant (Firazyr) — hereditary angioedema (acute attacks); Ziconotide (Prialt) — severe chronic pain refractory to systemic analgesics, intrathecal morphine.
- Tag: FDA-Approved · Rare Disease vs FDA-Approved · Pain.